Drug Profile
ORIC 101
Alternative Names: ORIC-101Latest Information Update: 29 Dec 2023
Price :
$50
*
At a glance
- Originator ORIC Pharmaceuticals
- Class Antineoplastics; Estrenes; Small molecules
- Mechanism of Action Glucocorticoid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Prostate cancer; Solid tumours
Most Recent Events
- 15 Dec 2023 ORIC Pharmaceuticals terminates a phase I trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA (PO) due to IND withdrawal (NCT03928314)
- 12 Dec 2023 Oric Pharmaceuticals announces IND withdrawal for ORIC-101 (NCT04033328)
- 04 Dec 2023 Oric Pharmaceuticals terminates phase I trial in Prostate cancer in the USA due to IND withdrawal (NCT04033328)